Statens Serum Institut, Copenhagen, Denmark.
Sanofi, Chilly-Mazarin, France.
J Infect Dis. 2022 Aug 12;226(Suppl 1):S29-S37. doi: 10.1093/infdis/jiac150.
Knowledge on age-specific hospitalizations associated with RSV infection is limited due to limited testing, especially in older children and adults in whom RSV infections are not expected to be severe. Burden estimates based on RSV coding of hospital admissions are known to underestimate the burden of RSV. We aimed to provide robust and reliable age-specific burden estimates of RSV-associated hospital admissions based on data on respiratory infections from national health registers and laboratory-confirmed cases of RSV.
We conducted multiseason regression analysis of weekly hospitalizations with respiratory infection and weekly laboratory-confirmed cases of RSV and influenza as covariates, based on national health registers and laboratory databases across 6 European countries. The burden of RSV-associated hospitalizations was estimated by age group, clinical diagnosis, and presence of underlying medical conditions.
Across the 6 European countries, hospitalizations of children with respiratory infections were clearly associated with RSV, with associated proportions ranging from 28% to 60% in children younger than 3 months and we found substantial proportions of admissions to hospital with respiratory infections associated with RSV in children younger than 3 years. Associated proportions were highest among hospitalizations with ICD-10 codes of "bronchitis and bronchiolitis." In all 6 countries, annual incidence of RSV-associated hospitalizations was >40 per 1000 persons in the age group 0-2 months. In age group 1-2 years the incidence rate ranged from 1.3 to 10.5 hospitalizations per 1000. Adults older than 85 years had hospitalizations with respiratory infection associated to RSV in all 6 countries although incidence rates were low.
Our findings highlight the substantial proportion of RSV infections among hospital admissions across different ages and may help public health professionals and policy makers when planning prevention and control strategies. In addition, our findings provide valuable insights for health care professionals attending to both children and adults presenting with symptoms of viral respiratory infections.
由于检测手段有限,尤其是在预期 RSV 感染不会严重的大龄儿童和成人中,有关 RSV 感染所致特定年龄段住院的知识有限。基于 RSV 住院编码的负担估计值已知会低估 RSV 的负担。我们旨在根据国家健康登记处的呼吸道感染数据和 RSV 的实验室确诊病例,提供基于数据的 RSV 相关住院负担的可靠和可靠的特定年龄段估计值。
我们针对 6 个欧洲国家的国家健康登记处和实验室数据库,针对每周呼吸道感染住院和每周实验室确诊的 RSV 和流感病例进行了多季节回归分析,并将其作为协变量。根据年龄组、临床诊断和潜在医疗条件,估计 RSV 相关住院的负担。
在 6 个欧洲国家中,儿童呼吸道感染住院与 RSV 明显相关,3 个月以下儿童的相关比例为 28%至 60%,我们发现 3 岁以下儿童因呼吸道感染住院的比例中,有相当一部分与 RSV 相关。与 ICD-10 代码“支气管炎和细支气管炎”相关的住院比例最高。在所有 6 个国家中,0-2 个月年龄组的 RSV 相关住院的年发生率均>40/1000 人。1-2 岁年龄组的发病率范围为每 1000 人中有 1.3 至 10.5 例住院。在所有 6 个国家中,85 岁以上的成年人都有与 RSV 相关的呼吸道感染住院,尽管发病率较低。
我们的发现强调了不同年龄段住院的 RSV 感染的比例很大,这可能有助于公共卫生专业人员和政策制定者在制定预防和控制策略时提供参考。此外,我们的发现为照顾因病毒性呼吸道感染而出现症状的儿童和成人的医疗保健专业人员提供了有价值的见解。